Clinical actionability enhanced through deep targeted sequencing of solid tumors.

ABSTRACT:

Background

Further advances of targeted cancer therapy require comprehensive in-depth profiling of somatic mutations that are present in subpopulations of tumor cells in a clinical tumor sample. However, it is unclear to what extent such intratumor heterogeneity is present and whether it may affect clinical decision-making. To study this question, we established a deep targeted sequencing platform to identify potentially actionable DNA alterations in tumor samples.

Methods

We assayed 515 formalin-fixed paraffin-embedded (FFPE) tumor samples and matched germline DNA (475 patients) from 11 disease sites by capturing and sequencing all the exons in 201 cancer-related genes. Mutations, indels, and copy number data were reported.

Results

We obtained a 1000-fold mean sequen

SUBMITTER: Chen K 

PROVIDER: S-EPMC4511273 | biostudies-literature | 2015 Mar

REPOSITORIES: biostudies-literature